The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
New acetabular system enhances precision, stability and robotic compatibility in total hip arthroplasty
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
Profitability came under strain. Gross profit fell to EUR 246m, with margins narrowing to 23.7% as negative product mix—particularly in Asia Pacific—weighed on performance
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
The move reinforces Croda’s push to fuel growth through high-impact innovation across its Consumer Care portfolio
While many cases are treatable, a subset can become highly aggressive, spreading to distant organs and resisting conventional therapies
The newly formed team is led by Tomabu Adjobimey, an immunologist known for his work in host-pathogen interactions and immune modulation
Analysts expect modest revenue growth but pressure on profitability in the March quarter
Genome editing holds extraordinary promise for treating previously incurable genetic diseases
Subscribe To Our Newsletter & Stay Updated
